EUCTR2015-001096-43-FR进行中（未招募）1 期
Treatment of superficial voluminous complicated slow-flow vascular malformations with sirolimus: a phase 2 trial in children observational-phase designed - PERFORMUS
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •* Patients aged from 6 years to 18 years (when submitting the intention letter, we aimed to include children from 12 months to 18 years. The minimal age was changed in the current protocol to children up to 6 years, because our protocol requires repeated MRI, which is non invasive imaging but requires sedation under the age of 5-6 years. We thus found too invasive to perform repeated sedations in toddlers)
- •* With a slow-flow VM confirmed by MRI, included or not into a genetic disorder, among the following:
- •- microcystic lymphatic malformation
- •- mixed micro- and macrocystic malformation
- •- venous malformation
- •- combined lymphatic and venous malformation
- •* Malformation voluminous (defined as = 5 % of body surface) and complicated (pain, functional impairment, bleeding, seepage)
- •* Extended to the underlying subcutaneous tissue, to the fascias, the muscles and/or the underlying bone
- •* MRI of the VM performed within 8 months
- •* Vaccination schedule updated
- •* Informed, written consent of the subject’s parents or the 18 years old subject (see §9.3 Screening and baseline visits)
- •* Cooperative parent or subject, aware of the necessity and duration of controls so that perfect adhesion to the protocol could be expected
- •* Subjects or subject’s parents covered by or having the rights to social security
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 45
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 5
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Non Inclusion criteria linked to the condition
- •?Slow-flow VMs which are only macrocystic lymphatic malformations
- •?Visceral life-threatening involvement
- •Non inclusion criteria linked to sirolimus
- •?Patients who received prior per os treatment with an mTOR inhibitor
- •?Immunosuppression (immunosuppressive disease or immunosuppressive treatment)
- •?Known chronic infectious disease
- •?History of cancer in the 2 previous years
- •?Brest feeding or pregnant women, or women on childbearing age without effective contraception, up to 12 weeks after treatment discontinuation
- •?Known allergy to mTOR inhibitor
- •?Concomitant treatment that inhibits or activates CYP3A4, and P-gp glycoprotein, cytotoxic drugs, antilymphocyte immunoglobulines and metoclopramide
- •?Intolerance to fructose, intolerance or malabsorption to glucose, galactose, metabolic insufficiency in sucrase-isomaltase, metabolic defect in lactase
- •?Known allergy to peanuts or soyabean
- •?Liver insufficiency (elevated transaminases > 2.5 N)
- •?Anemia with Hb < 9 g/dl
- •?Leukopenia < 1000/mm3
- •?Thrombocytopenia < 80 000/mm3
- •?Hypercholesterolemia (LDL-cholesterol = 2g/l)
- •?Patients with risk of opportunistic infections
- •?Live attenuated vaccine up to 3 months after sirolimus discontinuation
- •Other non inclusion criteria
- •?Contraindication of MRI
- •?Known allergy to lidocaïne (only for patients who accept genetic analysis1)
- •?Subject already participating to a therapeutic study
研究者
相似试验
已完成
2 期
suPERficial Slow-flow Vascular malFORMations Treated With sirolimUSVascular MalformationNCT02509468University Hospital, Tours63
招募中
4 期
Treatment of single and multiple soft tissue recessions of Miller classes I, II and III with a new reconstructive tissue matrix using the coronally displaced tunnel technique. A prospective clinical two-center cohort study.GINGIVAREZESSIONENK05Gingivitis and periodontal diseasesDRKS00023201Oral Reconstruction Foundation40
招募中
2 期
Treatment of larger tumor volumes or >= 2 lung tumors simultaneously in lung cancer patients using SBRT in a mean-lung dose escalation study10029107Non small cell lung cancer10038666lung cancerNL-OMON41422Antoni van Leeuwenhoek Ziekenhuis35
已完成
不适用
Minimally invasive surfactant therapy and diaphragm activity in preterm infantsRespiratory distress syndromerespiratory problems of newborn preterm infants10028971NL-OMON46170Academisch Medisch Centrum20
招募中
4 期
Three non-invasive Treatment Options for superficial basal cell carcinoma: PDT vs. imiquimod vs. 5-fluorouracil10040900skin cancerbasal cell carcinomaNL-OMON31670Academisch Medisch Centrum600